electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has achieved significant recognition by ranking #125 on the Financial Times' 'The Americas' Fastest Growing Companies 2025' list. The company secured this position based on its compound annual revenue growth between 2020 and 2023.
In the healthcare & life sciences sector, which represented 10% of the fastest-growing companies, electroCore ranked 16th among 30 healthcare companies, alongside notable peers like BeiGene, Hims & Hers Health, and Progyny. The company specializes in providing drug-free solutions for pain management, stress reduction, and sleep improvement.
The prestigious Financial Times ranking, now in its sixth year, was announced on April 2, 2025, featuring 300 top-performing companies across various sectors in the Americas.
electroCore (Nasdaq: ECOR), un'azienda di medicina bioelettronica e benessere, ha ottenuto un riconoscimento significativo classificandosi al #125 nella lista 'The Americas' Fastest Growing Companies 2025' del Financial Times. L'azienda ha raggiunto questa posizione in base alla sua crescita annuale composta dei ricavi tra il 2020 e il 2023.
Nel settore della salute e delle scienze della vita, che rappresenta il 10% delle aziende in più rapida crescita, electroCore si è classificata al 16° posto tra 30 aziende sanitarie, insieme a nomi noti come BeiGene, Hims & Hers Health e Progyny. L'azienda si specializza nell'offrire soluzioni senza farmaci per la gestione del dolore, la riduzione dello stress e il miglioramento del sonno.
Il prestigioso ranking del Financial Times, giunto alla sua sesta edizione, è stato annunciato il 2 aprile 2025, includendo 300 aziende ad alte prestazioni in vari settori delle Americhe.
electroCore (Nasdaq: ECOR), una empresa de medicina bioelectrónica y bienestar, ha logrado un reconocimiento significativo al ubicarse en el puesto #125 de la lista 'The Americas' Fastest Growing Companies 2025' del Financial Times. La compañía aseguró esta posición en base a su crecimiento anual compuesto de ingresos entre 2020 y 2023.
En el sector de salud y ciencias de la vida, que representó el 10% de las empresas de más rápido crecimiento, electroCore ocupó el 16° lugar entre 30 empresas de salud, junto a notables competidores como BeiGene, Hims & Hers Health y Progyny. La empresa se especializa en proporcionar soluciones sin medicamentos para la gestión del dolor, la reducción del estrés y la mejora del sueño.
El prestigioso ranking del Financial Times, que ahora se encuentra en su sexto año, fue anunciado el 2 de abril de 2025, presentando 300 empresas de alto rendimiento en varios sectores de las Américas.
electroCore (Nasdaq: ECOR), 생체 전자 의학 및 웰빙 회사는 'The Americas' Fastest Growing Companies 2025' 리스트에서 125위로 올라서며 중요한 인정을 받았습니다. 이 회사는 2020년부터 2023년까지의 연평균 수익 성장률을 기반으로 이 위치를 확보했습니다.
헬스케어 및 생명 과학 부문에서는 가장 빠르게 성장하는 기업의 10%를 차지하며, electroCore는 30개의 헬스케어 회사 중 16위에 올랐습니다. BeiGene, Hims & Hers Health, Progyny와 같은 저명한 동료들과 함께했습니다. 이 회사는 약물 없는 통증 관리, 스트레스 감소 및 수면 개선 솔루션을 제공하는 데 전문화하고 있습니다.
권위 있는 Financial Times 순위는 이제 6년째를 맞이하며, 2025년 4월 2일에 발표되어 아메리카 전역의 다양한 분야에서 300개의 우수 기업을 포함하고 있습니다.
electroCore (Nasdaq: ECOR), une entreprise de médecine bioélectronique et de bien-être, a obtenu une reconnaissance significative en se classant au #125 de la liste 'The Americas' Fastest Growing Companies 2025' du Financial Times. L'entreprise a sécurisé cette position en fonction de sa croissance annuelle composée des revenus entre 2020 et 2023.
Dans le secteur de la santé et des sciences de la vie, qui représentait 10 % des entreprises à la croissance la plus rapide, electroCore s'est classée 16e parmi 30 entreprises de santé, aux côtés de pairs notables tels que BeiGene, Hims & Hers Health et Progyny. L'entreprise se spécialise dans la fourniture de solutions sans médicaments pour la gestion de la douleur, la réduction du stress et l'amélioration du sommeil.
Le prestigieux classement du Financial Times, maintenant dans sa sixième année, a été annoncé le 2 avril 2025, présentant 300 entreprises performantes dans divers secteurs des Amériques.
electroCore (Nasdaq: ECOR), ein Unternehmen für bioelektronische Medizin und Wellness, hat durch die Platzierung auf Platz #125 in der Liste 'The Americas' Fastest Growing Companies 2025' des Financial Times bedeutende Anerkennung erlangt. Das Unternehmen sicherte sich diese Position basierend auf seinem jährlichen Umsatzwachstum zwischen 2020 und 2023.
Im Gesundheits- und Lebenswissenschaftssektor, der 10% der am schnellsten wachsenden Unternehmen ausmacht, belegte electroCore den 16. Platz unter 30 Gesundheitsunternehmen, zusammen mit namhaften Mitbewerbern wie BeiGene, Hims & Hers Health und Progyny. Das Unternehmen ist auf die Bereitstellung von medikamentenfreien Lösungen zur Schmerzbewältigung, Stressreduktion und Schlafverbesserung spezialisiert.
Das renommierte Ranking des Financial Times, das nun im sechsten Jahr veröffentlicht wird, wurde am 2. April 2025 bekannt gegeben und umfasst 300 leistungsstarke Unternehmen aus verschiedenen Sektoren in Amerika.
- None.
- None.
ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of “The Americas’ Fastest Growing Companies 2025.” Debuting at number 125, electroCore joins 300 other companies dominating in their respective sectors.
This is the sixth annual list that the Financial Times published, ranking companies based on the highest compound annual revenue growth between the years 2020 and 2023. The healthcare & life sciences sector represented
“electroCore delivers substantial value to our customers, offering a drug-free method for addressing pain, reducing stress, and improving sleep,” stated Joshua Lev, CFO of electroCore. “The ranking by the Financial Times reflects this value, as well as the hard work of our team to commercialize our innovative technology.”
The Americas’ Fastest Growing Companies 2025 list was announced on April 2, 2025, and can be currently viewed on the Financial Times website.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize electroCore’s products, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
What ranking did electroCore (ECOR) achieve in the Financial Times' 2025 fastest-growing companies list?
How did electroCore (ECOR) perform in the healthcare sector rankings?
What is the time period considered for electroCore's (ECOR) growth evaluation?
What are the main products or solutions offered by electroCore (ECOR)?
Which other healthcare companies were listed alongside electroCore (ECOR) in the FT ranking?
